Complete side-effect profile
All incidence rates are from ATTAIN-1 phase 3 trial (highest 36 mg dose vs. placebo, 72 weeks). The profile is consistent with injectable GLP-1s.
| Side effect | Incidence | Severity | Management |
|---|---|---|---|
| Nausea | 24% | Mild-moderate | Bland diet days 1-3 of each dose step; ginger 250-500mg; Zofran if persistent |
| Diarrhea | 16% | Transient | Hydration + electrolytes; usually resolves week 2-3 |
| Constipation | 14% | Chronic if untreated | 25-35g fiber/day + 80oz water/day; soluble fiber (chia, oats) |
| Vomiting | 11% | Mild | Smaller portions, slower eating; severe = call prescriber |
| Decreased appetite | 10% | Expected | Therapeutic effect, not side effect — eat to target, not hunger |
| Abdominal pain | 7% | Mild typical; severe = call | Severe pain radiating to back = rule out pancreatitis |
| Dyspepsia | 5% | Mild | PPI as needed; avoid large fatty meals |
| Fatigue | 4% | Mild | Usually transient; rule out dehydration + low protein |
Managing nausea — the protocol
Nausea is the #1 reason people quit a GLP-1 in month one. Most of it is preventable with simple changes. See our complete nausea management guide for the week-one survival protocol that works for ~80% of patients.
- Bland, low-fat, low-volume for 2 weeks after each dose increase
- Ginger 250-500 mg before meals — RCT-backed
- Stop eating at 70% full, wait 20 minutes, then decide
- Ondansetron (Zofran) 4 mg PRN — ask your prescriber if needed
Red flags — call your prescriber
Don't white-knuckle these. Call same-day:
- • Vomiting >24 hours, unable to keep fluids down
- • Severe abdominal pain radiating to back (possible pancreatitis)
- • Persistent yellow eyes/skin, dark urine (possible cholestasis)
- • New lump in neck, hoarseness, difficulty swallowing (possible thyroid)
- • Losing >2 lbs/week consistently (too-fast loss = muscle/face risk)
Side effects vs. injectable GLP-1s
The side-effect profile is similar to injectable GLP-1s — small differences in incidence rates but the same drug-class profile (predominantly GI, dose-dependent).
| Side effect | Foundayo (36mg) | Wegovy (2.4mg) | Zepbound (15mg) |
|---|---|---|---|
| Nausea | 24% | 44% | 29% |
| Diarrhea | 16% | 30% | 21% |
| Constipation | 14% | 24% | 17% |
| Discontinuation (AE) | 11.6% | 6.8% | 6.6% |
Foundayo has slightly lower individual symptom rates but higher overall discontinuation. The dropout pattern is concentrated in the dose-escalation weeks of each new step.
Frequently asked questions
- What are the most common side effects of Foundayo?
- Nausea (24%), diarrhea (16%), constipation (14%), vomiting (11%) — the same gastrointestinal profile as injectable GLP-1s. Most are mild-moderate and resolve within 2-3 weeks of each dose increase.
- Does Foundayo cause hair loss?
- Like other GLP-1s, ~5-7% of patients report hair shedding (telogen effluvium) from rapid weight loss stress — not the drug itself. Resolves at 6-9 months once weight stabilizes.
- Can Foundayo cause pancreatitis?
- Rare (<0.5% in trials) but documented. Severe abdominal pain radiating to the back is the warning sign. Stop the drug and seek emergency care.
- Is the boxed warning for thyroid cancer the same as Ozempic?
- Yes. Like all GLP-1s, Foundayo carries a boxed warning for thyroid C-cell tumors observed in rodent studies. Not for patients with personal or family history of medullary thyroid carcinoma or MEN-2.
- How long do Foundayo side effects last?
- Most GI side effects resolve within 2-3 weeks of each dose increase. By maintenance dose (week 17+), many patients report mild and intermittent symptoms; full absence of side effects is uncommon and should not be expected.
Educational only — not medical advice. If you experience side effects from Foundayo, contact your prescriber.